Immuneering Corporation
Biotechnology Research • 
Cambridge, Massachusetts, United States • 51-100 Employees
Company overview
| Headquarters | 245 Main Street, Second Floor, Cambridge, MA 02142, US |
| Phone number | +16175008080 |
| Website | |
| SIC | 283 |
| Keywords | Clinical Development, Oncology, Cancer Research, Drug Developement |
| Founded | 2008 |
| Employees | 51-100 |
| Socials |
Key Contacts at Immuneering Corporation
Ben Zeskind
Co-Founder And Ceo
Marty Hughes
Executive Director, Cmc
Stephen Sebastian
Executive Director, Corporate Controller
Jenny Zhang
Senior Director, Genomic Data Science
Adam Shiell
Executive Director, Regulatory Affairs
Christian Alaia
Senior Director Of Fp&A
Andrew Conrad
Associate Director, Cmc
Anna Travesa Centrich
Executive Director, Discovery
Elisabeth Madec Foley
Senior Director, Clinical Operations
Elisabeth Standard
Associate Director Scientific Project Management
Immuneering Corporation Email Formats
Immuneering Corporation uses 5 email formats. The most common is {first initial}{last name} (e.g., jdoe@immuneering.com), used 74.5% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@immuneering.com | 74.5% |
{first name}{last name} | johndoe@immuneering.com | 11.8% |
{last name}{last name} | doedoe@immuneering.com | 7.8% |
{first initial}.{last name} | j.doe@immuneering.com | 3.9% |
{first name}.{last name} | john.doe@immuneering.com | 2% |
About Immuneering Corporation
Immuneering is a clinical-stage oncology company focused on keeping cancer patients alive. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors. Immuneering’s lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily Deep Cyclic Inhibitor of MEK designed to improve durability and tolerability, and expand indications to include MAPK pathway-driven tumors such as most pancreatic cancers. Atebimetinib is currently in a Phase 2a trial in patients with advanced solid tumors including pancreatic cancer. The Company’s development pipeline also includes early-stage programs. For more information, please visit www.immuneering.com.
Immuneering Corporation revenue & valuation
| Annual revenue | $316,952 |
| Revenue per employee | $6,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $1,100,000 |
| Total funding | $255,000,000 |
Employees by Management Level
Total employees: 51-100
Seniority
Employees
Employees by Department
Immuneering Corporation has 29 employees across 8 departments.
Departments
Number of employees
Funding Data
Explore Immuneering Corporation's funding history, including investment rounds, total capital raised, and key backers.
Immuneering Corporation Tech Stack
Discover the technologies and tools that power Immuneering Corporation's digital infrastructure, from frameworks to analytics platforms.
UI frameworks
Video players
JavaScript libraries
Documentation
JavaScript libraries
Font scripts
JavaScript libraries
Programming languages
Blogs
SEO
Colombia
Saudi Arabia
Spain
United Kingdom
Frequently asked questions
4.8
40,000 users
